Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.

@article{Corbett2000InhibitionOC,
  title={Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.},
  author={Jeffrey W. Corbett and Soo S Ko and James D. Rodgers and L A Gearhart and Nicholas A. Magnus and Lee Bacheler and Sharon Diamond and SCOTTA. Jeffrey and Ronald M. Klabe and Beverly C Cordova and Sena Garber and Ken Logue and George L. Trainor and P. S. Anderson and Susan K Erickson-Viitanen},
  journal={Journal of medicinal chemistry},
  year={2000},
  volume={43 10},
  pages={
          2019-30
        }
}
A series of 4-alkenyl and 4-alkynyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones DPC 082 and DPC 083 and the 4-alkynyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones DPC 961 and DPC 963 were found to exhibit low nanomolar potency toward wild-type RF virus (IC(90) = 2.0, 2.1, 2.0… CONTINUE READING
Highly Cited
This paper has 18 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 citations